Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC
Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer
Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases
2 Commerce Drive
Cranbury, NJ 08512